Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors.
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Catheter Ablation
/ adverse effects
Electrodes
Feasibility Studies
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Lung
/ diagnostic imaging
Lung Neoplasms
/ diagnostic imaging
Male
Middle Aged
Pneumothorax
/ diagnosis
Postoperative Hemorrhage
/ diagnosis
Prospective Studies
Radiography, Interventional
Severity of Illness Index
Tomography, X-Ray Computed
Treatment Outcome
Journal
European review for medical and pharmacological sciences
ISSN: 2284-0729
Titre abrégé: Eur Rev Med Pharmacol Sci
Pays: Italy
ID NLM: 9717360
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
6
8
2019
pubmed:
6
8
2019
medline:
21
10
2020
Statut:
ppublish
Résumé
To assess the safety and feasibility of computed tomography-guided radiofrequency ablation (CT-guided RFA) in unresectable lung neoplasms, using a new 15G monopolar internally cooled wet electrode. 15 consecutive patients with lung neoplasms (< 4 cm), both primary and secondary, unsuitable for or refusing surgery, underwent percutaneous CT-guided RFA using a 15G electrode with a 3-cm exposed tip. The prevalence and grade of adverse events and technical success were evaluated, as well as the extension of the ablation zone, the complete response rates, and the time to progression, determined at CT examination performed 1, 6, and 12 months after the procedure. A total of 22 lung neoplasms were treated (mean diameter: 28 mm; range: 20-39 mm). Technical success was obtained in all patients, without major complications or intraprocedural deaths. Mild or moderate pneumothorax was registered in 46.7% of patients, while a perilesional hemorrhage was observed in 5/15 cases. During the follow-up period, a complete response was obtained in 19 out of 22 lesions (86.4%) with three partial response, two of them successfully retreated with the same technique. Percutaneous RFA using a 15G internally cooled wet electrode is a safe and feasible treatment for unresectable lung neoplasms, with high complete response rates.
Identifiants
pubmed: 31378896
doi: 10.26355/eurrev_201908_18541
pii:
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM